Miscellaneous
Our understanding of that landmark trial, the Women’s Health Initiative (WHI), continues to evolve. Data from younger women in the WHI, in addition to findings from the ELITE trial, suggest a favorable benefit/risk balance when menopausal hormone therapy is started within 10 years of the menopause transition or at age ≤ 60 years. As a result, the clinical guidelines for menopausal hormone therapy have changed. In addition, the SWAN study has provided us with a deeper understanding of women’s experiences during the menopause transition.